Q32 Bio Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $53.7M | $0 | $-6.7M | $3.2M | $34.0M | $2.7M | $1.7M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $19.2M | $48.1M | $31.7M | $98.4M | $93.1M | $100.4M | $89.4M |
| SG&A Expense | — | $17.7M | $18.0M | $9.9M | $38.1M | $36.8M | $32.6M | $22.2M |
| Operating Income | — | $16.9M | $-66.1M | $-48.3M | $-133.3M | $-95.9M | $-130.3M | $-109.9M |
| Operating Margin | — | 31.5% | — | 725.5% | -4,154.6% | -282.4% | -4,821.0% | -6,599.2% |
| Interest Expense | — | — | — | $1.5M | — | — | — | — |
| Pretax Income | — | $29.8M | $-46.1M | $-87.1M | $1.2M | $-95.8M | — | — |
| Income Tax Expense | — | $0 | $21.0K | $318.0K | $715.0K | $0 | $0 | $0 |
| Net Income | — | $29.8M | $-47.7M | $-53.7M | $-5.0M | $-95.8M | $-128.7M | $-103.9M |
| Net Margin | — | 55.5% | — | 808.0% | -156.0% | -281.9% | -4,762.9% | -6,237.5% |
| EPS (Basic) | — | $2.42 | $-5.12 | $-153.96 | $-0.09 | $-1.73 | $-2.80 | $-2.47 |
| EPS (Diluted) | — | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 | $-2.80 | $-2.47 |
| Shares Outstanding (Basic) | 14.6M | 12.3M | 9.3M | 57.8M | 57.4M | 55.3M | 50.3M | 45.1M |
| Shares Outstanding (Diluted) | 14.6M | 12.3M | 9.7M | 57.8M | 57.4M | 55.3M | 50.3M | 45.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |